Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Corporation Investors

LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24ZGNX&src=ctag” target=”_blank”gt;$ZGNXlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
Prongay & Murray LLP (“GPM”), a national investors rights law
firm, announces that a class action lawsuit has been filed on behalf of
investors that acquired Zogenix, Inc. (“Zogenix” or the “Company”)
(NASDAQ: ZGNX)
securities between February 6, 2019 and April 8, 2019, inclusive
(the “Class Period”). Zogenix investors have until June 11, 2019 to
file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here
to participate.

If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.

On April 8, 2019, Zogenix announced that it received a refusal to file
letter from the U.S. Food and Drug Administration (“FDA”) regarding
Zogenix’s new drug application (“NDA”) for FINTEPLA, Zogenix’s proposed
treatment for seizures associated with Dravet syndrome. The FDA
determined that the NDA was not sufficiently complete to permit a
substantive review because certain non-clinical studies were not
submitted to allow assessment of the chronic administration of
fenfluramine, and the application contained an incorrect version of a
clinical dataset. On this news, shares of Zogenix fell $11.89 or nearly
23% to close at $39.96 per share on April 9, 2019, thereby injuring
investors.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) Zogenix’s NDA for
FINTEPLA contained inadequate non-clinical data and an incorrect version
of a clinical dataset; (2) consequently, Zogenix’s NDA for FINTEPLA was
unlikely to gain FDA approval; and (3) as a result, the Company’s public
statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Zogenix during the Class Period you may move
the Court no later than June 11, 2019 to ask the Court
to appoint you as lead plaintiff. To be a member of the Class you need
not take any action at this time; you may retain counsel of your choice
or take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century
Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com,
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
www.glancylaw.com
shareholders@glancylaw.com